Mineralocorticoid antagonists in chronic kidney disease

Current Opinion in Nephrology and Hypertension

Volumn 26, Issue 1, 2017, Pages 50-55

  Al Dhaybi, Omar ^a   Bakris, George ^a  

^a UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

Author keywords

Aldosterone; Chronic kidney disease; Hyperkalemia; Mineralocorticoid receptor antagonists; Proteinuria

Indexed keywords

ALDOSTERONE; ANGIOTENSIN RECEPTOR ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; MINERALOCORTICOID ANTAGONIST;

ALBUMINURIA; BLOOD PRESSURE; CHRONIC KIDNEY FAILURE; DISEASE COURSE; DRUG EFFECT; HUMAN; HYPERKALEMIA; KIDNEY FUNCTION; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; REVIEW; SAFETY; CHEMICALLY INDUCED; COMBINATION DRUG THERAPY; DRUG EFFECTS; PHASE 3 CLINICAL TRIAL (TOPIC);

ALBUMINURIA; ANGIOTENSIN RECEPTOR ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; BLOOD PRESSURE; CLINICAL TRIALS, PHASE III AS TOPIC; DRUG THERAPY, COMBINATION; HUMANS; HYPERKALEMIA; MINERALOCORTICOID RECEPTOR ANTAGONISTS; RENAL INSUFFICIENCY, CHRONIC;

EID: 84991489135     PISSN: 10624821     EISSN: 14736543     Source Type: Journal    
DOI: 10.1097/MNH.0000000000000290     Document Type: Review

References (54)

1. Carney EF. Epidemiology: Global Burden of Disease Study 2013 reports that disability caused by CKD is increasing worldwide. Nat Rev Nephrol 2015; 11:446.
2. Bomback AS, Klemer PJ. Mineralocorticoid receptor blockade in chronic kidney disease. Blood Purif 2012; 33:119-124.
3. Toto RD. Aldosterone blockade in chronic kidney disease: can it improve outcome? Curr Opin Nephrol Hypertens 2010; 19:444-449.
4. Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Eng J Med 1999; 341:709-717.
5. Williams B, MacDonald TM, Morant S, et al., British Hypertension Society's PATHWAY Studies Group. Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): A randomised, double-blind, crossover trial. Lancet 2015; 386:2059-2068.
6. Oxlund CS, Henriksen JE, Tarnow L, et al. Low dose spironolactone reduces blood pressure in patients with resistant hypertension and type 2 diabetes mellitus: A double blind randomized clinical trial. J Hypertens 2013; 31:2094-2102.
7. Bianchi S, Batinin V, Bigazzi R. The renal effects of mineralocorticoid receptor antagonists. Int J Cardiol 2015; 200:20-24.
8. Brem AS, Gong R. Therapeutic targeting of aldosterone: A novel approach to the treatment of glomerular disease. Clin Sci (Lond) 2015; 128: 527-535.
9. DeMarco VG, Habibi J, Jia G, et al. Low-dose mineralocorticoid receptor blockade prevents western diet-induced arterial stiffening in female mice. Hypertension 2015; 66:99-107.
10. Martin-Fernandez B, Rubio-Navarro A, Cortegano I, et al. Aldosterone induces renal fibrosis and inflammatory M1-macrophage subtype via mineralocorticoid receptor in rats. PLoS One 2016; 11:e0145946.
11. Epstein M, Duprez DA. Resistant hypertension and the pivotal role for mineralocorticoid receptor antagonists: A clinical update 2016. Am J Med 2016; 129:661-666.
12. Bernadri S, Toffoli B, Zennaro C, et al. Aldosterone effects on glomerular structure and function. J Renin Angiotensin Aldosterone Syst 2015; 16:730-738.
13. Kadoya H, Satoh M, Sasaki T, et al. Excess aldosterone is a critical danger signal for inflammasome activation in the development of renal fibrosis inmice. FASEB J 2015; 29:3899-3910.
14. Amador CA, Barrientos V, Penã J, et al. Spironolactone decreases DOCAsalt-induced organ damage by blocking the activation of T helper 17 and the downregulation of regulatory T lymphocytes. Hypertension 2014; 63:797-803.
15. Haller H, Bertram A, Stahl K, et al. Finerenone: A new mineralocorticoid receptor antagonist without hyperkalemia: an opportunity in patients with CKD? Curr Hypertens Rep 2016; 18:41.
16. Sun QL, Li M, Rui HL, et al. Inhibition of local aldosterone by eplerenone reduces renal structural damage in a novel model of chronic cyclosporine A nephrotoxicity. J Renin Angiotensin Aldosterone Syst 2015; 16: 301-310.
17. Barrera-Chimal J, Pérez-Villalva R, Ortega JA, et al. Mild ischemic injury leads to long-term alterations in the kidney: amelioration by spironolactone administration. Int J Biol Sci 2015; 11:892-900.
18. Hirsch JS, Drexler Y, Bomback AS. Aldosterone blockade in chronic kidney disease. Semin Nephrol 2014; 34:307-322.
19. Ueda K, Nagase M. Mineralocorticoid receptor activation as an etiological factor in kidney diseases. Clin Exp Nephrol 2014; 18:16-23.
20. Lee HA, Song MJ, Seok YM, et al. Histone deacetylase 3 and 4 complex stimulates the transcriptional activity of the mineralocorticoid receptor. PLoS One 2015; 10:e0136801.
21. Bomback AS. Mineralocorticoid receptor antagonists in end-stage renal disease: efficacy and safety. Blood Purif 2016; 41:166-170.
22. Hung SC, Tarng DC. Reversed association between aldosterone and mortality in hemodialysis patients: role of volume overload. Steroids 2016; 111:60-62.
23. Gomez-Sanchez EP. Third-generation mineralocorticoid receptor antagonists: why do we need a fourth? J Cardiovasc Pharmacol 2016; 67:26-38.
24. Voelkl J, Alesutan I, Leibrock CB, et al. Spironolactone ameliorates PIT1-dependent vascular osteoinduction in klotho-hypomorphic mice. J Clin Invest 2013; 123:812-822.
25. Lang F, Ritz E, Voelkl J, et al. Vascular calcification: is aldosterone a culprit? Nephrol Dial Transplant 2013; 28:1080-1084.
26. Mizuiri S, Ohashi Y. ACE and ACE2 in kidney disease. World J Nephrol 2015; 4:74-82.
27. Tikellis C, Brown R, Head GA, et al. Angiotensin-converting enzyme 2 mediates hyperfiltration associated with diabetes. Am J Physiol Renal Physiol 2014; 306:F773-F780.
28. Vukusich A, Kunstmann S, Varela C, et al. A randomized, double-blind, placebo-controlled trial of spironolactone on carotid intima-media thickness in nondiabetic hemodialysis patients. Clin J Am Soc Nephrol 2010; 5:1380-1387.
29. Flevari P, Kalogeropoulou S, Drakou A, et al. Spironolactone improves endothelial and cardiac autonomic function in non heart failure hemodialysis patients. J Hypertens 2013; 31:1239-1244.
30. Lin C, Zhang Q, Zhang H, et al. Long-term effects of low-dose spironolactone on chronic dialysis patients: A randomized placebo controlled study. J Clin Hypertens 2016; 18:121-128.
31. Ojeda-Cervantes M, Barrera-Chimal J, Alberu J, et al. Mineralocorticoid receptor blockade reduced oxidative stress in renal transplant recipients: A double-blind, randomized pilot study. Am J Nephrol 2013; 37:481-490.
32. Sternlicht H, Bakris GL. Management of hypertension in diabetic nephropathy: how low should we go? Blood Purif 2016; 41:139-143.
33. Hou J, Xiong W, Cao L, et al. Spironolactone add-on for preventing or slowing the progression of diabetic nephropathy: A meta-analysis. Clin Ther 2015; 37:2086-2103.
34. Bomback AS, Kshirsagar AV, Amamoo MA, et al. Change in proteinuria after adding aldosterone blockers to ACE inhibitors or angiotensin receptor blockers in CKD: A systematic review. Am J Kidney Dis 2008; 51:199-211.
35. Bolignano D, Palmer SC, Navaneethan SD, et al. Aldosterone antagonists for preventing the progression of chronic kidney disease. Cochrane Database Syst Rev 2014; 4:CD007004.
36. Ando K, Ohtsu H, Uchida S, et al., EVALUATE Study Group. Antialbuminuric effect of the aldosterone blocker eplerenone in nondiabetic hypertensive patients with albuminuria: A double-blind, randomised, placebo-controlled trial. Lancet Diabetes Endocrinol 2014; 2:944-953.
37. Bianchi S, Bigazzi R, Campese VM. Long-term effects of spironolactone on proteinuria and kidney function in patients with chronic kidney disease. Kidney Int 2006; 70:2116-2123.
38. Edwards NC, Steeds RP, Chue CD, et al. The safety and tolerability of spironolactone in patients with mild to moderate chronic kidney disease. Br J Clin Pharmacol 2012; 73:447-454.
39. Morales E, Millet VG, Rojas-Rivera J, et al. Renoprotective effects of mineralocorticoid receptor blockers in patients with proteinuric kidney diseases. Nephrol Dial Transplant 2013; 28:405-412.
40. Van Buren PN, Adams-Huet B, Nguyen M, et al. Potassium handling with dual renin-angiotensin system inhibition in diabetic nephropathy. Clin J Am Soc Nephrol 2014; 9:295-301.
41. Esteras R, Perez-Gomez MV, Rodriguez-Osorio L, et al. Combination use of medicines from two classes of renin-angiotensin system blocking agents: risk of hyperkalemia, hypotension, and impaired renal function. Ther Adv Drug Saf 2015; 6:166-176.
42. Khosla N, Kalaitzidis R, Bakris GL. Predictors of hyperkalemia risk following hypertension control with aldosterone blockade. Am J Nephrol 2009; 30:418-424.
43. Lazich I, Bakris GL. Prediction and management of hyperkalemia across the spectrum of chronic kidney disease. Semin Nephrol 2014; 34:333-339.
44. Pitt B, Bakris GL. New potassium binders for the treatment of hyperkalemia: current data and opportunities for the future. Hypertension 2015; 66:731-738.
45. Bushinsky DA, Williams GH, Pitt B, et al. Patiromer induces rapid and sustained potassium lowering in patients with chronic kidney disease and hyperkalemia. Kidney Int 2015; 88:1427-1433.
46. Weir MR, Bakris GL, Bushinsky DA, et al. Patiromer in patients with kidney disease and hyperkalemia receiving RAAS inhibitors. N Engl J Med 2015; 372:211-221.
47. Pitt B, Anker SD, Bushinsky DA, et al. Evaluation of the efficacy and safety of RLY5016, a polymeric potassium binder, in a double-blind, placebo-controlled study in patients with chronic heart failure (the PEARL-HF) trial. Eur Heart J 2011; 32:820-828.
48. Bakris GL, Pitt B, Weir MR, et al., AMETHYST-DN Investigators. Effect of patiromer on serum potassium level in patients with hyperkalemia and diabetic kidney disease. The AMETHYST-DN Randomized Clinical Trial. JAMA 2015; 314:151-161.
49. Weir MR, Bakris GL, Gross C, et al. Treatment with patiromer decreases aldosterone in patients with chronic kidney disease and hyperkalemia on renin-angiotensin system inhibitors. Kidney Int 2016; 90:696-704.
50. Packham DK, Rasmussen HS, Lavin P, et al. Sodium zirconium cyclosilicate in hyperkalemia. N Engl J Med 2015; 372:222-231.
51. Kosiborod M, Rasmussen HS, Lavin P, et al. Effect of sodium zirconium cyclosilicate on potassium lowering for 28 days among outpatients with hyperkalemia; the HARMONIZE randomized clinical trial. JAMA 2014; 312:2223-2233.
52. Bakris GL, Agarwal R, Chan JC, et al. Effect of finerenone on albuminuria in patients with diabetic nephropathy: A randomized clinical trial. JAMA 2015; 314:884-894.
53. Pitt B, Kober L, Ponikowski P, et al. Safety and tolerability of the novel nonsteroidal mineralocorticoid receptor antagonist BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease: A randomized, double-blind trial. Eur Heart J 2013; 34:2453-2463.
54. Hill NR, Lasserson D, Thompson B, et al. Benefits of Aldosterone Receptor Antagonism in Chronic Kidney Disease (BARACK D) trial-A multicentre, prospective, randomised, open, blinded end-point, 36-month study of 2,616 patients within primary care with stage 3b chronic kidney disease to compare the efficacy of spironolactone 25 mg once daily in addition to routine care on mortality and cardiovascular outcomes versus routine care alone: study protocol for a randomized controlled trial. Trials 2014; 15:160.